Provided by Tiger Trade Technology Pte. Ltd.

IDEAYA Biosciences

37.36
-0.4500-1.19%
Post-market: 37.360.00000.00%19:30 EDT
Volume:579.05K
Turnover:21.67M
Market Cap:3.60B
PE:-19.10
High:38.54
Open:38.52
Low:37.00
Close:37.81
52wk High:42.68
52wk Low:26.05
Shares:96.27M
Float Shares:94.37M
Volume Ratio:0.71
T/O Rate:0.61%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.9561
EPS(LYR):-1.2849
ROE:-16.22%
ROA:-11.54%
PB:3.00
PE(LYR):-29.08

Loading ...

IDEAYA Biosciences Up Over 17%, on Pace for Largest Percent Increase Since April 2023 -- Data Talk

Dow Jones
·
Apr 13

Wedbush Adjusts Price Target on IDEAYA Biosciences to $58 From $52, Maintains Outperform Rating

MT Newswires Live
·
Apr 13

Ideaya Biosciences rises 22.8%

TIPRANKS
·
Apr 13

IDEAYA Biosciences Shares Rise 13% After Co's Eye Cancer Drug Combo Improves Survival in Trial

THOMSON REUTERS
·
Apr 13

Ideaya Biosciences Stock Jumps 16% on Eye Cancer Therapy Trial Results

Dow Jones
·
Apr 13

IDEAYA Eye Cancer Trial Data Beats Standard Therapy, Stock Soars

Benzinga_recent_news
·
Apr 13

Top Premarket Gainers

MT Newswires Live
·
Apr 13

Stock Track | IDEAYA Biosciences Soars 31.15% in Pre-market on Positive Phase 2/3 Trial Results for Eye Cancer Drug

Stock Track
·
Apr 13

Ideaya Biosciences Shares Jump on Trial Results

Dow Jones
·
Apr 13

BUZZ-IDEAYA Biosciences surges after eye cancer drug combo improves survival in trial

Reuters
·
Apr 13

Ideaya Biosciences, Servier announce topline results from OptimUM-02 trial

TIPRANKS
·
Apr 13

U.S. Stocks to Watch: Goldman Sachs, SanDisk, Exxon Mobil, Nvidia, Ideaya, and More

Tiger Newspress
·
Apr 13

Ideaya eye cancer drug meets main goal of mid-to-late-stage trial

Reuters
·
Apr 13

IDEAYA says darovasertib-crizotinib trial cuts progression risk 58% in metastatic uveal melanoma

Reuters
·
Apr 13

IDEAYA Biosciences Shares Gain 18% Premarket Ahead of Data Release for Its Experimental Cancer Drug

THOMSON REUTERS
·
Apr 13

IDEAYA Biosciences Inc - Trial Met Primary Endpoint Showing Statistically Significant Improvement in Median Pfs by Bicr

THOMSON REUTERS
·
Apr 13

IDEAYA Biosciences Inc - Nda Submission Planned for Second Half of 2026 to Support U.S. Accelerated Approval

THOMSON REUTERS
·
Apr 13

IDEAYA Biosciences and Servier Announce Positive Topline Results From Phase 2/3 Registrational Trial (Optimum-02) of Darovasertib in Combination With Crizotinib in First-Line Hla-a*02:01-Negative Metastatic Uveal Melanoma

THOMSON REUTERS
·
Apr 13

Why IDEAYA Biosciences Shares Are Trading Higher By 18%; Here Are 20 Stocks Moving Premarket

Benzinga_recent_news
·
Apr 13

Analysts Offer Insights on Healthcare Companies: IDEAYA Biosciences (IDYA) and Certara (CERT)

TIPRANKS
·
Apr 13